Parmax Pharma Faces Intense Selling Pressure Amid Significant Price Declines

Parmax Pharma Ltd is currently facing significant selling pressure, with the stock showing only sellers today. The company has experienced consecutive days of losses, with a notable decline of 9.98% in just one day, compared to a minimal drop of 0.20% in the Sensex. Over the past week, Parmax Pharma's performance has worsened by 10.63%, while the Sensex fell by 2.23%.
In the last month, the stock has declined by 11.66%, significantly underperforming the Sensex, which decreased by 7.18%. The three-month performance reveals a stark drop of 21.97% for Parmax Pharma, against the Sensex's 9.90% decline. Year-to-date, the stock is down 13.15%, while the Sensex has fallen by 6.66%.

Despite a strong one-year performance of 21.46%, Parmax Pharma's three-year performance shows a decline of 14.60%, contrasting sharply with the Sensex's growth of 34.24%. The stock's erratic trading pattern, with no trades on one day out of the last 20, and its intraday low of Rs 39.4, indicate heightened volatility. Additionally, while the stock is above its 200-day moving average, it remains below its 5-day, 20-day, 50-day, and 100-day moving averages, suggesting a challenging market position.